Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Pro Medicus Limited ( (AU:PME) ) has issued an announcement.
Pro Medicus Limited has reported a small increase in the shareholding of director Peter Terence Kempen, reflecting a further on-market investment in the company. Kempen holds his interest directly and through related entities, including a superannuation fund and EMK Investments Pty Ltd, where he is a director and beneficial owner.
The filing shows Kempen acquired 400 additional ordinary shares on 23 February 2026 at $116.43 per share, lifting his total holding to 630,082 shares. The transaction, executed as an on-market purchase, signals continued alignment of the director’s financial interests with those of other shareholders, though it represents only a modest incremental change in overall ownership.
The most recent analyst rating on (AU:PME) stock is a Hold with a A$137.00 price target. To see the full list of analyst forecasts on Pro Medicus Limited stock, see the AU:PME Stock Forecast page.
More about Pro Medicus Limited
Pro Medicus Limited is a health imaging IT company that provides radiology and medical imaging software solutions. The company focuses on delivering advanced picture archiving, communication, and visualization systems to hospitals, imaging centers, and other healthcare providers, supporting clinical workflows and diagnostic efficiency.
Average Trading Volume: 306,009
Technical Sentiment Signal: Hold
Current Market Cap: A$12.85B
See more insights into PME stock on TipRanks’ Stock Analysis page.